Safety Assessment of the Meningococcal B Vaccine in the UK

Introduction to the Meningococcal B Vaccine

Researchers aimed to evaluate whether the meningococcal B vaccine, part of the UK infant immunization program, complied with established safety guidelines. The 4CMenB vaccine received its first license in Europe in 2013 after undergoing rigorous clinical trials that assessed its safety and efficacy. Although the trials revealed unexpected side effects, such as fever and skin reactions when administered alongside other vaccines, the vaccine was still considered safe for further studies.

Inclusion in the UK Immunization Program

In 2015, the meningococcal B vaccine was incorporated into the United Kingdom’s infant immunization schedule. It is administered to infants at eight and 16 weeks of age, followed by a booster at one year. Prior studies indicated a 94% effectiveness rate within the first ten months of the program.

Study Aims and Methodology

Research Objectives

A study published in The Lancet Child Adolescent Health journal sought to further investigate the safety of the meningococcal B vaccine. Led by Bryan and colleagues, the research utilized the Yellow Card Scheme—an initiative designed to report adverse vaccine reactions.

Criteria for Adverse Reaction Assessment

The researchers applied six criteria to evaluate the severity of reported adverse reactions, which ranged from medically significant events to fatalities. The study focused on children aged 18 months or younger, assessing incidents such as death, local reactions, Kawasaki disease, fever, and seizures.

Findings on Vaccine Side Effects

Independent Vaccination and Reports

To minimize confounding symptoms, the meningococcal B vaccine was administered alone, without accompanying vaccines. This approach did not hinder parental consent for future vaccinations. Approximately 1.29 million doses were administered, translating to about three million doses over a 20-month period.

Concerns Raised by Yellow Card Reports

Of the reported doses, around 52% raised concerns. Notably, there were no reports of bacterial infections. Among the adverse events, 364 cases of fever were recorded, with 58% categorized as serious, typically indicating high fever. Seizures accounted for 6% of reports, with a higher incidence linked to subsequent doses. Skin infections made up 41% of the reports, with 120 labeled as serious. Three cases of Kawasaki disease were noted, though a direct link to vaccinations remains unproven. Additionally, subcutaneous nodules lasting several months were found in nearly half of the cases with local reactions, but insufficient data limited further understanding of this phenomenon.

Limitations of the Study

Challenges with the Yellow Card Reporting Tool

The Yellow Card reporting tool has inherent limitations, including potential under-reporting of adverse reactions. Moreover, the reports do not establish causation between the vaccine and the reported events. Further data and research are necessary to investigate rare adverse events. Issues also arise with electronic data collection, such as delays in data transmission between hospitals and the risk of missing information.

Overall Safety Assessment

Despite the limitations, the collected data aligned with expectations based on prior statistical analyses. The vaccine demonstrated benefits with minimal safety concerns. Researchers emphasized the need for ongoing long-term studies and monitoring to maintain safety standards.

Reference

Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: A prospective surveillance study. Lancet Child Adolesc Health. 2018;2(6):395-403. doi:10.1016/S2352-4642(18)30103-2.